Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 19, 2016. The document serves as a transaction notification regarding a change in shareholding by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of a specific securities transaction.
Material Changes
The filing reports an increase in the notional interest in Ordinary Shares for Mr. P C Thomson, SVP of Communications & Government Affairs. This increase resulted from the re-investment of dividends paid on July 14, 2016, under the Company's 2009 Deferred Annual Bonus Plan.
Transaction Details
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Date: July 14, 2016.
- Transaction Price: £16.285 per share.
- Total Volume: 386.22 shares.
- Composition: The volume includes both personal contributions and matching shares.
Outlook, Risks, and Management Commentary
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a routine disclosure of an employee share plan transaction.
Key Facts for Investor Verification
- Verify the total shareholding of Mr. P C Thomson post-transaction to assess insider ownership levels.
- Confirm the terms of the 2009 Deferred Annual Bonus Plan regarding dividend re-investment and matching share calculations.
- Note that this filing does not reflect the company's broader financial health or operational results for the period.